View Cart  

MannKind Beset With Afrezza Clinical Trial Fraud Allegations

A A
Less than two months before the FDA makes a decision on its inhaled insulin Afrezza, MannKind is facing allegations of clinical trial improprieties from a former employee.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00